

Freedom of Information Request – 6572

Q1. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with: - January to March 2022 data used

- **Abemaciclib (Verzenios) + aromatase inhibitor *** - 0
- **Abemaciclib (Verzenios) + Fulvestrant (Faslodex)** - 0
- **Alpelisib (Piqray) + Fulvestrant (Faslodex)** - 0
- **Atezolizumab (Tecentriq)**** - 1
- **Bevacizumab (Avastin)** - 0
- **Eribulin (Halaven)** - 3
- **Everolimus (Afinitor) + Exemestane** - 0
- **Fulvestrant (Faslodex) as a single agent** - 0
- **Gemcitabine + paclitaxel** - 0
- **Herceptin (Trastuzumab) + paclitaxel** - 3
- **Herceptin (Trastuzumab) as a single agent** - 12
- **Lapatinib (Tyverb)** - 0
- **Neratinib (Nerlynx)** - 0
- **Olaparib (Lynparza)** - 0
- **Palbociclib (Ibrance) + aromatase inhibitor*** - 1
- **Palbociclib (Ibrance) + Fulvestrant (Faslodex)** - 0
- **Pertuzumab (Perjeta) + trastuzumab + docetaxel** - 3
- **Ribociclib (Kisqali) + aromatase inhibitor*** - 0
- **Ribociclib (Kisqali) + Fulvestrant (Faslodex)** - 0

- **Talazoparib (Talzenna) - 0**
- **Trastuzumab emtansine (Kadcyla) - 1**
- **Other active systemic anti-cancer therapy ** - unable to answer unless there is a list of specific drugs**

*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole

**eg. docetaxel, vinorelbine or capecitabine as a single agent

Q2. For the above patients, how many of these received their first ever dose for each product line?

- *Herceptin (Trastuzumab) + paclitaxel – 1*
- *Herceptin (Trastuzumab) as a single agent – 1*
- *Pertuzumab (Perjeta) + trastuzumab + docetaxel – 1*

All other answers for Q2 are 0.